Soligenix advances COVID-19 vaccine

By The Science Advisory Board staff writers

July 28, 2020 -- Biopharmaceutical firm Soligenix said that preclinical immunogenicity studies of its CiVax heat stable subunit COVID-19 vaccine candidate demonstrated that both broad-spectrum antibody immunity and cell-mediated rapid onset immunity are possible using the CoVaccine HT adjuvant.

Authored by collaborators from the University of Hawaiʻi at Mānoa, the article has been submitted to npj Vaccines for peer review. A manuscript preprint is available at bioRxiv.org.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.